Product Image
Invitrogen™

Flp-In™ Complete System

Notre système complet Flp-In™ permet l’intégration et l’expression de votre gène d’intérêt dans les cellules de mammifères à un emplacementAfficher plus
Have Questions?
RéférenceQuantité
K6010011 kit
Référence K601001
Prix (EUR)
2 935,00
Each
Quantité:
1 kit
Prix (EUR)
2 935,00
Each
Notre système complet Flp-In™ permet l’intégration et l’expression de votre gène d’intérêt dans les cellules de mammifères à un emplacement génomique spécifique. Le système Flp-In implique l’introduction du site de la cible de recombinaison Flp (FRT) dans le génome de lignée de cellules de mammifères de choix. Un vecteur d’expression contenant votre gène d’intérêt est alors intégré dans le génome via la recombinaison de l’ADN médiée par recombinase Flp au site FRT.

Les principaux composants du système Flp-In™ sont les suivants :

• Un vecteur de site cible Flp-In., pFRT⁄lacZeo, pour la génération d’une lignée de cellules hôtes contenant un site FRT intégré
• Un plasmide d’expression contenant un site FRT lié au gène de résistance à l’hygromycine pour l’intégration et la sélection médiées par recombinase Flp d’une lignée de cellules stables exprimant votre gène d’intérêt sous le contrôle de l’activateur⁄promoteur immédiat-précoce du cytomégalovirus (CMV) humain
• Un plasmide d’expression par recombinase Flp, pOG44, pour l’expression de la recombinase Flp sous le contrôle du promoteur CMV humain
• Un plasmide d’expression de contrôle contenant le gène de chloramphénicol acétyl transférase (CAT), qui, lorsqu’il est co-transfecté avec pOG44 dans la lignée de cellules hôte Flp-In., exprime CAT
Usage exclusivement réservé à la recherche. Ne pas utiliser pour des procédures de diagnostic.
Spécifications
Système constitutif ou inductibleConstitutive
Type de livraisonTransfection
À utiliser avec (application)Développement de lignées cellulaires stables, intégration ciblée
Type de produitSystème complet Flp-In
Quantité1 kit
Agent de sélection (eucaryotique)Zeocin™, hygromycine
VecteurpFRT
Méthode de clonageEnzyme de restriction / MCS
Gamme de produitsFlp-In, pcDNA
AccélérateurCMV
Marqueur de protéineNon étiqueté
Unit SizeEach
Contenu et stockage
Le système complet Flp-In™ comprend le kit principal (K601002), 1 g d’antibiotique Zeocin™ et 1 g d’hygromycine B. Tous les vecteurs sont superenroulés et lyophilisés. Conserver l’hygromycine à +4°C. Conserver tous les autres composants à -20°C. L’antibiotique Zeocin™ doit être protégé contre l’exposition à la lumière. La stabilité de tous les réactifs est garantie pendant 6 mois lorsqu’ils sont correctement conservés.

Foire aux questions (FAQ)

I performed the Flp-In reaction and obtained hygromycin-resistant clones which also turned out to be Zeocin antibiotic resistant and lacZ-positive. I am concerned that the Flp-In reaction has not worked. Can you explain what might be happening?

We have observed in-house that in cells where the FRT site has integrated into a very transcriptionally active locus in the host cell genome (seen more commonly in Flp-In CHO and Flp-In 293 cells but can also happen in Flp-In 3T3 cells and any other Flp-In host cell line), there is some "read-through" transcription and translation of the lacZ-Zeocin ORF subsequent to the Flp-In reaction, even though the lacZ-Zeocin ORF does not have a bonafide promoter and ATG. In such cases, the hygromycin-resistant clones would also be lacZ-positive and Zeocin antibiotic-resistant. To make sure that the integration is FRT site-specific and not random, we recommend doing a parallel control transfection with no pOG44 present. This should yield no surviving clones upon hygromycin selection, indicating that all the hygromycin-resistant clones obtained in the presence of pOG44 are indeed Flp recombinase-dependent and hence have the gene of interest integrated at the FRT site. Also, a Southern blot analysis of these clones will help verify that they do indeed have proper FRT integration of the gene of interest despite the expression of lacZ (although this is typically not necessary). After the Flp-In reaction, as long as you see hygromycin-resistant clones, we recommend that you select them and assay them for expression of your gene of interest.

Find additional tips, troubleshooting help, and resources within our Protein Expression Support Center.

I used the pcDNA5/FRT vector in your Flp-In 3T3 cell line and was initially able to express my gene of interest, but after a month or so, lost expression. Why is this?

The Flp-In 3T3 cell line is derived from NIH3T3 cells, which are mouse fibroblast cells. The CMV promoter is known to get silenced over time in murine cell lines and hence we would recommend using a Flp-In expression vector with a non-CMV promoter in these cells, such as the pEF5/FRT/V5-D-TOPO vector or the pEF5/FRT/V5-DEST vector.

I used the pFRT/lacZeo vector to generate my own Flp-In host cell line and then made my Flp-In expression cell line. I am seeing very poor expression of my gene of interest. Is there anything else I can try to improve expression?

Before giving up, we would suggest that you try using the pFRT/lacZeo2 vector to generate your host cell line. This vector contains a truncated version of the SV40 promoter driving the lacZ-Zeocin fusion. Use of this vector facilitates the isolation of clones that have integrated the vector near enhancer elements in the genome, thus resulting in higher levels of expression of the gene of interest.

What is the difference between the Jump-In and Flp-In systems?

The Jump-In system is PhiC31-integrase mediated and is a stable, targeted, and irreversible mammalian expression system. It consists of the Jump-In Fast system that involves a single integration step and the Jump-InTI (targeted integration) system that needs two integration steps, both of which are targeted and irreversible. In contrast, the Flp-In system is a stable, targeted mammalian expression system that is reversible. The first integration is random (integration of pFRT/lacZeo), and the second integration (integration of the Flp-In expression vector) is targeted but reversible.

Is multiple integration of the Flp-In expression construct possible? How do you screen for multiple integrants, and how stable is the Flp-In expression cell line?

In theory, one can get multiple integrations of the Flp-In expression construct—an FRT-specific integration event and a random, second-site integration. However, random integration is a relatively uncommon event. Limiting the amount of DNA in the transfection will reduce the chance of second-site integration. We have transfected 293 cells (lacking the FRT site) with the pcDNA5/FRT vector and have identified one potential second-site integrant after screening over 200 clones. DNA integrations can be detected by Southern blot. A single integrant will display a single band; double: two; triple: three, etc. We have maintained a number of Flp-In expression cell lines for over four months and have not observed any loss of the Flp-In expression construct, whether hygromycin selection was maintained or not.

Find additional tips, troubleshooting help, and resources within our Protein Expression Support Center.

Citations et références (15)

Citations et références
Abstract
Directed mutagenesis in region 713-720 of human thyroperoxidase assigns 713KFPED717 residues as being involved in the B domain of the discontinuous immunodominant region recognized by human autoantibodies.
Authors:Bresson D, Pugnière M, Roquet F, Rebuffat SA, N-Guyen B, Cerutti M, Guo J, McLachlan SM, Rapoport B, Estienne V, Ruf J, Chardès T, Péraldi-Roux S,
Journal:J Biol Chem
PubMed ID:15150267
'Autoantibodies (aAbs) to thyroid peroxidase (TPO), the hallmark of autoimmune thyroid disease (AITD), recognize conformational epitopes restricted to an immunodominant region (IDR), divided into two overlapping domains A and B. Despite numerous efforts aimed at localizing the IDR and identifying aAb-interacting residues on TPO, only two critical amino acids, Lys(713) ... More
Does mPER2 protein oscillate without its coding mRNA cycling?: post-transcriptional regulation by cell clock.
Authors:Fujimoto Y, Yagita K, Okamura H,
Journal:Genes Cells
PubMed ID:16629904
'Does the mammalian oscillatory protein mPER2 show the rhythm without its coding mRNA cycling? Here we answer this question by inserting a single copy of exogenous mPer2 gene to a NIH3T3 fibroblasts cell line, using Flp-In system. We generated the stable cell lines which constantly express mRNAs coding either N-terminal ... More
Unlike Diablo/smac, Grim promotes global ubiquitination and specific degradation of X chromosome-linked inhibitor of apoptosis (XIAP) and neither cause apoptosis.
Authors:Silke J, Kratina T, Ekert PG, Pakusch M, Vaux DL,
Journal:J Biol Chem
PubMed ID:14570909
'Grim is a Drosophila inhibitor of apoptosis (IAP) antagonist that directly interferes with inhibition of caspases by IAPs. Expression of Grim, or removal of DIAP1, is sufficient to activate apoptosis in fly cells. Transient expression of Grim in mammalian cells induces apoptosis, arguing for the conservation of apoptotic pathways, but ... More
Genetic analysis of the herpes simplex virus type 1 UL20 protein domains involved in cytoplasmic virion envelopment and virus-induced cell fusion.
Authors:Melancon JM, Foster TP, Kousoulas KG,
Journal:J Virol
PubMed ID:15220406
'The herpes simplex virus type 1 UL20 protein (UL20p) is an important determinant for cytoplasmic virion morphogenesis and virus-induced cell fusion. To delineate the functional domains of the UL20 protein, we generated a panel of single and multiple (cluster) alanine substitutions as well as UL20p carboxyl-terminal truncations. The UL20 mutant ... More
Localization of the discontinuous immunodominant region recognized by human anti-thyroperoxidase autoantibodies in autoimmune thyroid diseases.
Authors:Bresson D, Cerutti M, Devauchelle G, Pugnière M, Roquet F, Bes C, Bossard C, Chardès T, Péraldi-Roux S,
Journal:J Biol Chem
PubMed ID:12501244
'The discontinuous immunodominant region (IDR) recognized by autoantibodies directed against the thyroperoxidase (TPO) molecule, a major autoantigen in autoimmune thyroid diseases, has not yet been completely localized. By using peptide phage-displayed technology, we identified three critical motifs, LXPEXD, QSYP, and EX(E/D)PPV, within selected mimotopes which interacted with the human recombinant ... More